Article
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Cancer medicine - 1 Sept 2020
Zhou Ye, Zhang Xinhua, Wu Xiaojun, Zhou Yongjian, Zhang Bo, Liu Xiufeng, Wu Xin, Li Yan, Shen Lin, Li Jian
Abstract excerpt
AIM: Dasatinib is a small molecule tyrosine kinase inhibitor with multiple targets including kit, PDGFR, and SRC. This prospective study evaluated the efficacy and safety of dasatinib as third-line treatment for gastrointestinal stromal tumors (GIST). METHODS: The study enrolled adult patients (≥18 years of age) with histologically confirmed unresectable and/or metastatic GIST whose disease progressed despite...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.